Adolor Corporation Presenting Clinical Data on First-in-Class Gastrointestinal Compound at Annual Meeting of American Pain Society

- Presentation Available at www.adolor.com -



Apr 20, 2001, 01:00 ET from Adolor Corporation

    EXTON, Pa., April 20 /PRNewswire Interactive News Release/ -- Adolor
 Corporation (Nasdaq:   ADLR) announced today that it will be participating in a
 panel presentation at the annual meeting of the American Pain Society in
 Phoenix, Arizona. The panel, entitled, "Recent Advances in the Treatment of
 Opioid Bowel Dysfunction and Postoperative Ileus," will take place on
 Saturday, April 21, and will include previously unpublished clinical data on
 ADL 8-2698, an oral, non-absorbed small molecule opioid receptor antagonist to
 treat post-operative ileus and opioid bowel dysfunction.
     William K. Schmidt, Ph.D., Vice President of Adolor, will moderate the
 symposium. A Power Point version of the presentation will be posted tomorrow
 on the Company's website at http://www.adolor.com, in the "Investor Relations"
 section.
 
     About Post-Operative Ileus.  Each year, approximately 5 million patients
 undergo abdominal surgery, such as hysterectomy, colectomy and caesarean
 section and the majority of these patients develop a form of temporary bowel
 paralysis known as post-operative ileus. This prolongs recovery from surgery
 and extends the length of hospital stay, causes patient distress, and adds
 significant cost to treating surgical patients.
 
     Adolor Corporation discovers, develops and plans to commercialize
 proprietary pharmaceutical products for the treatment of pain and to mitigate
 the side effects that are caused by current pain treatments. Adolor has a
 portfolio of product candidates in development in Phase 1 to Phase 3 clinical
 trials. These products include our peripheral opioid analgesics and
 ADL 8-2698, which is intended to reduce the most prevalent and severe side
 effects of current opioid narcotics, such as nausea and vomiting, as well as
 treat the symptoms of opioid-induced bowel dysfunction, such as constipation.
 Adolor's product candidates target peripheral opioid receptors and are not
 expected to exhibit the dose-limiting side effects of existing opioid
 narcotics.
 
     Certain statements made in this press release related to Adolor products,
 as well as any therapeutic applications and outcomes, may be deemed to be
 forward-looking statements. Such statements involve risks and uncertainties.
 Among the factors that could cause actual results to differ materially from
 those set forth in these statements are the risk that the clinical trials for
 Adolor's product candidates may not be successful, Adolor may not obtain
 necessary regulatory approvals for its product candidates and the risks and
 other factors detailed, from time to time, in Adolor's filings with the
 Securities and Exchange Commission, including Adolor's Registration Statement
 on Form S-1.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X53642648
 
 

SOURCE Adolor Corporation
    EXTON, Pa., April 20 /PRNewswire Interactive News Release/ -- Adolor
 Corporation (Nasdaq:   ADLR) announced today that it will be participating in a
 panel presentation at the annual meeting of the American Pain Society in
 Phoenix, Arizona. The panel, entitled, "Recent Advances in the Treatment of
 Opioid Bowel Dysfunction and Postoperative Ileus," will take place on
 Saturday, April 21, and will include previously unpublished clinical data on
 ADL 8-2698, an oral, non-absorbed small molecule opioid receptor antagonist to
 treat post-operative ileus and opioid bowel dysfunction.
     William K. Schmidt, Ph.D., Vice President of Adolor, will moderate the
 symposium. A Power Point version of the presentation will be posted tomorrow
 on the Company's website at http://www.adolor.com, in the "Investor Relations"
 section.
 
     About Post-Operative Ileus.  Each year, approximately 5 million patients
 undergo abdominal surgery, such as hysterectomy, colectomy and caesarean
 section and the majority of these patients develop a form of temporary bowel
 paralysis known as post-operative ileus. This prolongs recovery from surgery
 and extends the length of hospital stay, causes patient distress, and adds
 significant cost to treating surgical patients.
 
     Adolor Corporation discovers, develops and plans to commercialize
 proprietary pharmaceutical products for the treatment of pain and to mitigate
 the side effects that are caused by current pain treatments. Adolor has a
 portfolio of product candidates in development in Phase 1 to Phase 3 clinical
 trials. These products include our peripheral opioid analgesics and
 ADL 8-2698, which is intended to reduce the most prevalent and severe side
 effects of current opioid narcotics, such as nausea and vomiting, as well as
 treat the symptoms of opioid-induced bowel dysfunction, such as constipation.
 Adolor's product candidates target peripheral opioid receptors and are not
 expected to exhibit the dose-limiting side effects of existing opioid
 narcotics.
 
     Certain statements made in this press release related to Adolor products,
 as well as any therapeutic applications and outcomes, may be deemed to be
 forward-looking statements. Such statements involve risks and uncertainties.
 Among the factors that could cause actual results to differ materially from
 those set forth in these statements are the risk that the clinical trials for
 Adolor's product candidates may not be successful, Adolor may not obtain
 necessary regulatory approvals for its product candidates and the risks and
 other factors detailed, from time to time, in Adolor's filings with the
 Securities and Exchange Commission, including Adolor's Registration Statement
 on Form S-1.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X53642648
 
 SOURCE  Adolor Corporation